Literature DB >> 17228022

Clinicopathologic and pedigree differences in amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status.

Laura Valle1, Jose Perea, Pablo Carbonell, Victoria Fernandez, Ana M Dotor, Javier Benitez, Miguel Urioste.   

Abstract

PURPOSE: To establish the clinicopathologic and familial differences within Amsterdam I-positive families, showing either tumor microsatellite instability (MSI) or microsatellite stability (MSS) in order to confirm or deny the existence of hereditary nonpolyposis colorectal cancer (HNPCC) without defects in the mismatch repair system. PATIENTS AND METHODS: Sixty-four Amsterdam I-positive families were included in the study for which full, three-generation, family medical histories and colorectal paraffin-embedded tumors were obtained. Both personal and clinicopathologic information of patients were collected. In all cases, both the MSI status and the mismatch repair (MMR) protein expression were analyzed. MMR genetic testing was performed on the MSI families.
RESULTS: Of the Amsterdam I-positive families, 59.4% were tumor MSI, and 40.6% were tumor MSS. When comparing both groups, the statistical differences were observed in the age of onset (MSI, 41 years; MSS, 53 years); in the colorectal tumor location, more frequently proximal in MSI cases; in fewer mucinous tumors in MSS; and loss of MMR protein expression in the MSI tumors. Regarding the individual and familial cancer history, we observed a predominance of individuals with multiple primary tumors in MSI pedigrees, as well as differences in the type of tumors developed within the family.
CONCLUSION: Our findings support the suspicion of another hereditary colorectal syndrome different from HNPCC and characterized by MSS, the normal MMR immunohistochemical expression, the presence of only colorectal tumors, and the absence of individuals with multiple primary tumors. All these circumstances suggest the existence of a non-MMR gene being responsible for this new syndrome.

Entities:  

Mesh:

Year:  2007        PMID: 17228022     DOI: 10.1200/JCO.2006.06.9781

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

1.  Familial colorectal cancer type X syndrome: two distinct molecular entities?

Authors:  Inês Francisco; Cristina Albuquerque; Pedro Lage; Hélio Belo; Inês Vitoriano; Bruno Filipe; Isabel Claro; Sara Ferreira; Paula Rodrigues; Paula Chaves; Carlos Nobre Leitão; António Dias Pereira
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

Review 2.  Lower gastrointestinal tract cancer predisposition syndromes.

Authors:  Neel B Shah; Noralane M Lindor
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

3.  Inherited colorectal cancer syndromes.

Authors:  Robert Gryfe
Journal:  Clin Colon Rectal Surg       Date:  2009-11

Review 4.  Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome.

Authors:  Noralane M Lindor
Journal:  Surg Oncol Clin N Am       Date:  2009-10       Impact factor: 3.495

5.  Microsatellite instability and promoter hypermethylation in colorectal cancer in India.

Authors:  V V Ravi Kanth; Sandeep Bhalsing; M Sasikala; G V Rao; R Pradeep; Urmila Steffie Avanthi; D Nageshwar Reddy
Journal:  Tumour Biol       Date:  2014-01-10

6.  Approach to early-onset colorectal cancer: clinicopathological, familial, molecular and immunohistochemical characteristics.

Authors:  Jose Perea; Edurne Alvaro; Yolanda Rodríguez; Cristina Gravalos; Eva Sánchez-Tomé; Barbara Rivera; Francisco Colina; Pablo Carbonell; Rogelio González-Sarmiento; Manuel Hidalgo; Miguel Urioste
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

7.  Familial colorectal cancer: eleven years of data from a registry program in Switzerland.

Authors:  Michal Kovac; Endre Laczko; Ritva Haider; Josef Jiricny; Hansjakob Mueller; Karl Heinimann; Giancarlo Marra
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

8.  Genotype-phenotype correlation in MMR mutation-positive families with Lynch syndrome.

Authors:  Lucía Pérez-Cabornero; Mar Infante; Eladio Velasco; Enrique Lastra; Cristina Miner; Mercedes Durán
Journal:  Int J Colorectal Dis       Date:  2013-04-16       Impact factor: 2.571

9.  Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer.

Authors:  Tara E Seery; Argyrios Ziogas; Bruce S Lin; Chuan-Ju G Pan; Michael J Stamos; Jason A Zell
Journal:  J Gastrointest Surg       Date:  2012-12-14       Impact factor: 3.452

10.  Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.

Authors:  Ashley S Case; Israel Zighelboim; David G Mutch; Sheri A Babb; Amy P Schmidt; Alison J Whelan; Stephen N Thibodeau; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.